Open AccessReal‐world experience using combination therapy with riociguat and risk assessment using REVEAL Lite 2.0 in patients with pulmonary arterial hypertension
Author(s) -
Sahay Sandeep,
Rahaghi Franck
Publication year - 2020
Publication title -
pulmonary circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.791
H-Index - 40
ISSN - 2045-8940
DOI - 10.1177/2045894020910098
Subject(s) - riociguat , medicine , ambrisentan , chronic thromboembolic pulmonary hypertension , tadalafil , pulmonary hypertension , cardiology , risk assessment , intensive care medicine , sildenafil , bosentan , receptor , computer security , endothelin receptor , computer science
Pulmonary arterial hypertension is a progressive disease that can lead to right‐sided ventricular failure and premature death. Tailoring therapy to individual patient’s needs, along with regular risk assessment, is integral for optimal outcomes in patients with pulmonary arterial hypertension. Results from the AMBITION trial support the use of upfront combination of tadalafil and ambrisentan. In a recent analysis of risk assessment in pulmonary arterial hypertension, abridged versions of the REVEAL 2.0 risk score were shown to be comparable to the full tools. In this report, we present a case series of the use of riociguat in upfront combination or sequentially, and the impact on risk scores as determined by the abridged REVEAL Lite 2.0 approach.